

**neuraxpharm Arzneimittel GmbH**

**Certificate of Analysis and Release**

Name, Strength/ Potency	NAXIVA-PANAXOL CBD 250 /32 ml Cann. Ext.
Dosage Form	standardized Cannabis extract (CBD 25% w/w; 243 mg/ml and THC 1.5 % w/w; 15 mg/ml) in MCT
Batch Number	24322KT01-1
Manufacturing Date	30.08.2022
Expiry Date	07/2024


Test	Specification	Results
Organoleptic properties (visual inspection, DAB 2022)	Homogenous greenish or yellow to brown liquid	complies
Relative density (EP* 2.2.5)	Indicative for individual product	0.978
Identification (TLC, EP* 2.2.27; DAB 2022)	Zonal pattern of test solution conforms to the zonal pattern of reference solution	complies
Assay – Cannabinoids concentration (HPLC; EP* 2.2.29; DAB 2021) CBD	95 - 110 % of CBD label claim	101% (25.22% (w/w))
$\Delta^9$ THC	95 - 110 % of THC label claim	100% (1.50% (w/w))
Vitamin E (HPLC, EP* 2.2.29)	$\geq 0.4\%$	0.63%
Heavy metals (EP* 2.4.27) Cadmium Lead Mercury	$\leq 1.0$ ppm $\leq 5.0$ ppm $\leq 0.1$ ppm	$< 0.05$ ppm $< 0.1$ ppm $< 0.05$ ppm
Toxins-Mycotoxins (EP* 2.8.18) Aflatoxin B1 Total Aflatoxins (B1, B2, G1, G2) Ochratoxin A	$\leq 2\mu\text{g/Kg}$ $\leq 4\mu\text{g/Kg}$ Negative	n.d. n.d. n.d.
Purity test (HPLC; EP* 2.2.29; DAB 2021) Cannabinol (CBN)	$\leq 2.5\%$	$< 0.1\%$ (w/w)


Microbiological quality (EP* 2.6.12; 2.6.31)		
TAMC	10 <sup>4</sup> CFU/g (max. acceptable count: 50000 CFU/g)	< 100
TYMC	10 <sup>2</sup> CFU/g (max. acceptable count: 500 CFU/g)	< 10
<i>Bile-tolerant gram-negative bacteria</i>	<10 <sup>2</sup> (CFU/g)	< 10
<i>Escherichia coli</i>	Absence (1 g)	negative
<i>Salmonella</i>	Absence (25 g)	negative
Residual Solvents		
Ethanol (GC)	≤ 5000 ppm	n.d.
Water content (EP* 2.5.12; DAB 2022)	≤ 0.5%	0.23% (w/w)

\*edition 10.6

Abbreviations: n.d.: not detectable; ppm: parts per million; EP: european pharmacopoeia; TLC: thin layer chromatography; TAMC: total aerobic microbial count; TYMC: total combined yeasts and molds count; CFU: colony-forming unit; HPLC: High performance liquid chromatography

This batch of product has been manufactured and tested in full compliance with the EU-GMP requirements. The tested batch complies with the specification and can be released.

22. MRZ. 2023   
**Issued by:**  
M. Sliwinski  
QA Specialist

22. MRZ. 2023   
**Approved by:**  
Dr. M. Schroers  
Head of QC

28. MRZ. 2023   
**Released by:**  
Dr. Jean-Paul M. Makosi  
Qualified Person